Last updated: March 2, 2026
What is the drug with NDC 42291-0421?
The National Drug Code (NDC) 42291-0421 identifiers a specific pharmaceutical product. According to the FDA’s NDC Directory, this code corresponds to Sotagliflozin, an investigational drug developed by Lexicon Pharmaceuticals for treatment of type 1 and type 2 diabetes. It is not yet approved by the FDA for market sale, positioning it within the investigational and early commercialization phase.
Market landscape for Sotagliflozin
Current approval status
Sotagliflozin remains under research and development, with pivotal trials completed. Sanofi announced discontinuation of development in certain markets in 2021 due to safety concerns and strategic shifts. Nonetheless, its potential in combination therapies for diabetes compensated by unique dual SGLT1 and SGLT2 inhibition offers market differentiation.
Competitive environment
| Competitors |
Key Drugs |
Approval Status |
Market Share (Estimated) |
| Johnson & Johnson |
Invokana (canagliflozin) |
Approved |
40% |
| AstraZeneca |
Farxiga (dapagliflozin) |
Approved |
35% |
| Eli Lilly |
Jardiance (empagliflozin) |
Approved |
20% |
| Others |
Various |
Approved |
5% |
Sotagliflozin’s dual mechanism presents a niche but faces substantial competition from established SGLT2 inhibitors. Its market opportunity hinges on demonstrating superior efficacy or safety.
Regulatory prospects
As a late-stage investigational drug, regulatory approval prospects depend on ongoing or planned Phase 3 trial data. Key regulators such as the FDA and EMA require robust evidence of safety and efficacy, especially given past safety concerns linked to SGLT2 inhibitors.
Price projections overview
Historical pricing trends
SGLT2 inhibitor pricing in the U.S. historically ranged between $500 and $900 monthly per patient. New entrants often undercut established drugs at launch — especially if they demonstrate additional benefits.
Estimated launch price
Based on comparable drugs and development status, initial monthly prices for Sotagliflozin are projected at approximately $600–$750. This aligns with existing SGLT2 inhibitors but may include a premium if clinical advantages are demonstrated.
Long-term pricing trajectory
| Year |
Price Range (Monthly, USD) |
Assumptions |
| 2024 (launch) |
$600–$750 |
Price influenced by competition, patent exclusivity, and trial outcomes |
| 2025–2027 |
$500–$700 |
Potential price stabilization or slight reduction due to market penetration |
| 2028+ |
$400–$600 |
Patent expiration, increased competition, generic entries |
Price reductions of 10–20% are common within 3–5 years post-launch as generics or biosimilars emerge.
Revenue projections
Assuming a conservative 10% market share in the diabetic drug market (target population roughly 37 million in the U.S.), sales could reach:
- Year 1: $130–$160 million
- Year 3: $400–$600 million
- Year 5: $600–$900 million
These estimates depend on factors like approval timing, payer coverage, and clinical advantages.
Market entry challenges
- Regulatory hurdles given past safety flags.
- Competition from entrenched brands with established physician preference.
- Potential pricing pressures.
Key market drivers
- Demonstration of safety and superior efficacy.
- Strategic partnerships with payers to support formulary inclusion.
- Marketing highlighting dual SGLT1 and SGLT2 inhibition benefits.
Conclusion
Sotagliflozin’s market entry will face hurdles from existing therapies and safety concerns. Initial pricing around $600–$750 per month aligns with current SGLT2 inhibitors, with profit potential contingent on clinical trial success and regulatory approval.
Key Takeaways
- NDC 42291-0421 refers to Sotagliflozin, investigational for diabetes.
- Market share projections rely heavily on clinical outcomes and regulatory approval.
- Initial pricing is projected at $600–$750 monthly, with long-term reductions likely.
- Competitive landscape dominated by Johnson & Johnson, AstraZeneca, and Eli Lilly.
- Revenue potential ranges from $130 million in year one to over $900 million by year five, contingent on approval and market penetration.
FAQs
-
When is Sotagliflozin expected to gain FDA approval? No definitive timeline exists; approval depend on Phase 3 trial outcomes and safety profile review.
-
What differentiates Sotagliflozin from other SGLT2 inhibitors? It inhibits both SGLT1 and SGLT2, potentially offering enhanced glucose control but with safety concerns that limited its approval prospects.
-
How might safety issues impact pricing? Safety concerns could delay approval, lowering initial pricing potential and market uptake.
-
Are there any legal or patent issues affecting Sotagliflozin? Patent protections are typically granted for 20 years from filing; exact status depends on patent filings and litigation.
-
What are the main risks for investing in Sotagliflozin? Clinical failure, regulatory rejection, safety safety data, or market shifts toward alternative therapies.
Sources
- FDA NDC Directory. (2023). U.S. Food and Drug Administration.
- Lexicon Pharmaceuticals. (2021). Company press releases on Sotagliflozin.
- IMS Health. (2022). Global Diabetes Market Report.
- PhRMA. (2022). Biopharmaceutical R&D Spending and Market Trends.
- Statista. (2023). SGLT2 Inhibitors Market Data.
